Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.17.21 - Glutamate carboxypeptidase II

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Acquired Immunodeficiency Syndrome
GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity.
Adenocarcinoma
68Ga-Labeled Prostate-Specific Membrane Antigen Uptake in Pheochromocytoma: An Incidental Finding in PET/CT Scan.
A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
Cloning and characterization of the prostate-specific membrane antigen promoter.
Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.
Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen.
Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques.
GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.
Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy.
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis.
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT.
Intense fluoro-2-deoxyglucose uptake in high-grade prostatic adenocarcinoma with negligible prostate-specific membrane antigen expression.
Loss of PSMA Expression in Non-neuroendocrine Dedifferentiated Acinar Prostate Cancer.
Making the Case for Prostate-Specific Membrane Antigen-Targeted Positron Emission Tomography/Computed Tomography in Suspected Prostate Cancer.
Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase).
Monoclonal antibodies and prostate-specific membrane antigen.
Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.
Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.
New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.
Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions.
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.
Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma.
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Prostate-specific membrane antigen.
PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells.
Radium and other alpha emitters in prostate cancer.
Recombinant Adenovirus Mediated Prostate-Specific Enzyme Pro-Drug Gene Therapy Regulated by Prostate-Specific Membrane Antigen (PSMA) Enhancer/Promoter.
Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma.
Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
The use of nested RT-PCR of prostate-specific membrane antigen in blood cells: implications for the detection of haematogenous neoplastic cells in patients with prostate adenocarcinoma.
Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer.
Adenomatous Polyps
Genetic Variation in Glutamate Carboxypeptidase II and Interaction with Dietary Natural Vitamin C May Predict Risk for Adenomatous Polyp Occurrence.
Adrenocortical Carcinoma
Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma.
Prostate-Specific Membrane Antigen Expression in Adrenocortical Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma.
Alzheimer Disease
Expression of glutamate carboxypeptidase II in human brain.
Glutamate carboxypeptidase II does not process amyloid-? peptide.
Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.
Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain.
N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases.
NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.
Amyotrophic Lateral Sclerosis
Expression of glutamate carboxypeptidase II in human brain.
Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models.
N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases.
NAALADase inhibition protects motor neurons against chronic glutamate toxicity.
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Anencephaly
Role of parental folate pathway single nucleotide polymorphisms in altering the susceptibility to neural tube defects in South India.
Angiofibroma
Advantage of 68Ga-PSMA PET/CT on Postradiotherapy Response Assessment of Juvenile Nasal Angiofibroma.
Comparison of 68Ga-PSMA PET/CT and Contrast-Enhanced MRI on Residual Disease Assessment of Juvenile Nasal Angiofibroma.
Fusion 68Ga-Prostate-Specific Membrane Antigen PET/MRI on Postoperative Surveillance of Juvenile Nasal Angiofibroma.
Physiological PSMA Uptake in the Tubarial Salivary Glands and Its Implications in the PARIS Protocol-A First Study of Its Kind!
Pterygoid Base Pneumatization Simulating Residual Disease-A Pitfall of Structural Imaging in Juvenile Nasal Angiofibroma.
Validation of Postoperative Angiofibroma Radionuclide Imaging Study (PARIS) Protocol Using PSMA PET/CT-A Proof of Concept Study.
Angiolipoma
Prostate-specific membrane antigen expressing angiolipoma.
aspartoacylase deficiency
Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain.
Ataxia Telangiectasia
Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer.
Blindness
RasGRF1 disruption causes retinal photoreception defects and associated transcriptomic alterations.
Bone Neoplasms
Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain: [La ketamine et un inhibiteur N-acetylaspartylglutamate peptidase exercent une analgesie sur la douleur du cancer des os].
Brain Diseases
Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes.
Brain Injuries
Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats.
Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury.
Neuroprotective effects of N-acetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia.
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.
Suppression of Glutamate Carboxypeptidase II Ameliorates Neuronal Apoptosis from Ischemic Brain Injury.
Brain Injuries, Traumatic
Glutamate carboxypeptidase II gene knockout attenuates oxidative stress and cortical apoptosis after traumatic brain injury.
Metabolite differences between glutamate carboxypeptidase II gene knockout mice and their wild-type littermates after traumatic brain injury: a 7-tesla 1H-MRS study.
Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury.
Brain Ischemia
Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG.
Brain Neoplasms
Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer.
Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.
Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain.
The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
Breast Neoplasms
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
68Ga-PSMA PET/CT in the evaluation of locally advanced and metastatic breast cancer, a single center experience.
Association of glutamate carboxypeptidase II (GCPII) haplotypes with breast and prostate cancer risk.
Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis.
Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators.
Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.
Combined impact of polymorphism of folate metabolism genes; glutamate carboxypeptidase, methylene tetrahydrofolate reductase and methionine synthase reductase on breast cancer susceptibility in kashmiri women.
EV-Ident: Identifying Tumor-Specific Extracellular Vesicles by Size Fractionation and Single-Vesicle Analysis.
Long Half-life (89)Zr Labeled Radiotracers Can Guide In Suite Percutaneous Molecular Imaging PET/CT-guided Biopsies Without Reinjection of Radiotracer.
Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines.
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.
Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
Prostate-specific membrane antigen in breast carcinoma.
Canavan Disease
Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain.
RasGRF1 disruption causes retinal photoreception defects and associated transcriptomic alterations.
Carcinogenesis
Association of glutamate carboxypeptidase II (GCPII) haplotypes with breast and prostate cancer risk.
Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain.
Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.
Carcinoma
18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
68Ga-PSMA Expression in Pseudoangiomatous Stromal Hyperplasia of the Breast.
A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine.
A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.
Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.
Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine.
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.
Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing.
Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.
Cerebellar Metastases From Prostate Cancer on 68Ga-PSMA PET/CT.
Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma.
Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer.
Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters.
Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).
Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)-Proof of concept and initial imaging results.
Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.
Discrepancy between Multiparametric Magnetic Resonance Imaging and 68Ga Prostate-Specific Membrane Antigen Positron Emission Tomography: A Simultaneous Acquired Positron Emission Tomography-Magnetic Resonance Imaging Case.
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.
Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Expression of prostate-specific membrane antigen in normal and malignant human tissues.
Expression of prostate-specific membrane antigen in renal cortical tumors.
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?
Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma.
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer.
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis.
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line.
Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging.
In Vivo Visualization of Prostate-Specific Membrane Antigen in Adenoid Cystic Carcinoma of the Salivary Gland.
In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma.
Incidental Detection of Hepatocellular Carcinoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.
Incidental Detection of Type B2 Thymoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT Imaging.
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
Intense fluoro-2-deoxyglucose uptake in high-grade prostatic adenocarcinoma with negligible prostate-specific membrane antigen expression.
Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity.
Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11.
Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence.
Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.
Lymphangitic Carcinomatosis From Prostate Cancer Identified With Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography Imaging.
Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy.
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.
Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results.
Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy.
Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.
Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII.
Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.
Optimization of Labeling PSMA(HBED) with Ethanol-Postprocessed (68)Ga and Its Quality Control Systems.
Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review.
Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.
PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY.
Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.
Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging.
Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.
Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck.
Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy.
Prostate-specific membrane antigen directed selective thrombotic infarction of tumors.
Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain.
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Prostate-specific membrane antigen: evidence for the existence of a second related human gene.
PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma.
PSMA expression on neovasculature of solid tumors.
PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.
PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings.
PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.
Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid.
Re; Seniaray N, Verma R, Khanna S, Belho E, Pruthi A, Mahajan H. Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence. Indian J Urol 2020;36:191-9.
Real-world Israeli single institution experience with PET-PSMA for staging of patients with clinically staged localized prostate carcinoma.
Rectal Carcinoma on 68Ga-PSMA PET/CT.
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function.
Serous Cystadenoma of the Pancreas Showing Uptake on 68Ga PSMA PET/CT.
Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Subacute Cortical Infarct Showing Uptake on 68Ga-PSMA PET/CT.
Targeted Radionuclide Therapy: A Historical and Personal Review.
The application of prostate specific membrane antigen in CART?cell therapy for treatment of prostate carcinoma (Review).
The cloning and characterization of a second brain enzyme with NAAG peptidase activity.
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.
The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma.
The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma.
Triple synchronous tumours of the urinary system with different histologies: a case report.
Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma - Is PSMA-PET-CT a helpful tool in radiation oncology?
Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications.
Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease.
Utility of (68) Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.
What's behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.
Widespread Metastatic Prostate Carcinoma Shown by 68Ga-PSMA PET/CT.
[Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma]
Carcinoma, Adenoid Cystic
In Vivo Visualization of Prostate-Specific Membrane Antigen in Adenoid Cystic Carcinoma of the Salivary Gland.
Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck.
Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid.
Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma - Is PSMA-PET-CT a helpful tool in radiation oncology?
Carcinoma, Hepatocellular
A Case of Well-differentiated Hepatocellular Carcinoma Identified on Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT.
Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma.
Incidental Detection of Hepatocellular Carcinoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging.
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma.
Carcinoma, Merkel Cell
Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma.
Carcinoma, Non-Small-Cell Lung
Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer.
Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.
Carcinoma, Renal Cell
18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.
Expression of prostate-specific membrane antigen in renal cortical tumors.
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.
Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.
PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings.
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease.
Utility of (68) Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.
Carcinoma, Small Cell
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Carcinoma, Squamous Cell
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
Carcinoma, Transitional Cell
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?
Cardiovascular Diseases
Influence of a glutamate carboxypeptidase II (GCPII) polymorphism (1561C-->T) on plasma homocysteine, folate and vitamin B(12) levels and its relationship to cardiovascular disease risk.
Central Nervous System Diseases
Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay.
Cholangiocarcinoma
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Colitis
FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.
Colitis, Ulcerative
Inflammatory bowel disease and prostate cancer risk: A systematic review.
Colorectal Neoplasms
In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile.
Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in Egyptian patients.
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.
The reduced folate carrier (RFC1) 80G > A and folate hydrolase 1 (FOLH1) 1561C > T polymorphisms and the risk of colorectal cancer: a nested case-referent study.
The reduced folate carrier (RFC1) 80G>A and folate hydrolase 1 (FOLH1) 1561C>T polymorphisms and the risk of colorectal cancer: a nested case-referent study.
Confusion
Clearing up the confusion over the glutamate carboxypeptidase II gene.
Coronary Artery Disease
Oxidative Stress is Associated with Genetic Polymorphisms in One-Carbon Metabolism in Coronary Artery Disease.
Crohn Disease
Inflammatory bowel disease and prostate cancer risk: A systematic review.
Dementia
Topics of nuclear medicine research in Europe.
Diabetes Mellitus, Type 2
Androgen receptor overexpression in prostate cancer in type 2 diabetes.
Diabetic Neuropathies
GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.
Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3.
The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy.
Diverticulum
Intense 68Ga-PSMA Uptake in Diverticulum of the Sigmoid Colon.
Encephalomyelitis
Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis.
Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis.
Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.
Epilepsy
Expression of glutamate carboxypeptidase II in human brain.
N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases.
Fasciitis
Low 68Ga-PSMA PET/CT Uptake in Chronic Intramuscular Nodular Fasciitis.
Fibroma
Prostate-Specific Membrane Antigen in Low-Grade Fibromatosis.
Folic Acid Deficiency
Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: Implications for neurodevelopmental disorders.
Gastrointestinal Stromal Tumors
Incidental finding of ileal gastrointestinal stromal tumour during prostate cancer staging with prostate-specific membrane antigen scan.
Glioblastoma
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients.
In vivo visualization of prostate-specific membrane antigen in glioblastoma.
Prostate-Specific Membrane Antigen (PSMA) Promotes Angiogenesis of Glioblastoma Through Interacting With ITGB4 and Regulating NF-?B Signaling Pathway.
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.
Prostate-Specific Membrane Antigen Expression in Neovasculature of Glioblastoma Multiforme.
PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging.
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.
Glioma
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade.
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.
Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas.
Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.
Gliosarcoma
The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
Hearing Loss
RasGRF1 disruption causes retinal photoreception defects and associated transcriptomic alterations.
Hemangioma
Does Prostate-Specific Membrane Antigen Avidity of Vertebral Hemangioma Change?
Prostate-Specific Membrane Antigen PET/CT Findings for Hepatic Hemangioma.
Hemangiosarcoma
Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
Prostate-Specific Membrane Antigen Expression in Metastatic Angiosarcoma Detected on 18F-PMSA PET/CT: A New Potential Prognostic Marker.
Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
Huntington Disease
Expression of glutamate carboxypeptidase II in human brain.
Hydronephrosis
Renal Pelvis Metastasis From Prostatic Adenocarcinoma Missed by PSMA PET: A Case Report.
Hyperalgesia
Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain.
GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.
Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat.
Hyperemia
2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia.
Hyperhomocysteinemia
Genetic and environmental influences on total plasma homocysteine and coronary artery disease (CAD) risk among South Indians.
Glutamate carboxypeptidase II (GCPII) genetic variants as determinants of hyperhomocysteinemia: implications in stroke susceptibility.
Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia.
Hyperkalemia
Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis.
Hypertension
Genetic and environmental influences on total plasma homocysteine and coronary artery disease (CAD) risk among South Indians.
Machine learning algorithm-based risk prediction model of coronary artery disease.
Infarction, Middle Cerebral Artery
Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG.
Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats.
Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation.
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.
Infections
ALTERED MERISTEM PROGRAM1 has conflicting effects on the tolerance to heat shock and symptom development after Pseudomonas syringae infection.
Multi-component Polymeric System for Tumour Cell-Specific Gene Delivery Using a Universal Bungarotoxin Linker.
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Inflammatory Bowel Diseases
Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs.
FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.
Inflammatory bowel disease and prostate cancer risk: A systematic review.
Jejunal brush-border folate hydrolase. A novel enzyme.
N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Influenza, Human
A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer.
Ischemic Stroke
Early-onset ischaemic stroke: analysis of 58 polymorphisms in 17 genes involved in methionine metabolism.
Keloid
Prostate-specific membrane antigen expression in regeneration and repair.
Kidney Neoplasms
Blood-based RT-PCR assays of MN/CA9 or PSMA: clinical application in renal cancer patients.
Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion.
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Leukemia
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Lipoma
Incidental Finding of Hibernoma in Prostate-Specific Membrane Antigen PET/CT.
Liposarcoma
Incidental Detection of Tracer Avidity in Liposarcoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.
Liver Cirrhosis
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Liver Neoplasms
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Synthesis and Biochemical Evaluation of Samarium-153 Oxide Nanoparticles Functionalized with iPSMA-Bombesin Heterodimeric Peptide.
Lung Neoplasms
68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer.
Comprehensive evaluation of the response of genes to the administration of the antitumor drug S-1 using a low density array.
Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer.
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance.
Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.
Lymphatic Metastasis
68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy.
A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients.
Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.
Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review.
Diagnostic Performance of ??Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis.
Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer.
Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis.
Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
Salvage surgery for nodal recurrent prostate cancer.
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia.
Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Lymphedema
Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema.
Lymphoma
Relevance of radiobiological concepts in radionuclide therapy of cancer.
Lymphoma, B-Cell
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Lymphoma, Mantle-Cell
Relevance of radiobiological concepts in radionuclide therapy of cancer.
Lymphoma, Non-Hodgkin
Prostate-Specific Membrane Antigen Uptake in Small Cleaved B-Cell Follicular Non-Hodgkin Lymphoma.
Relevance of radiobiological concepts in radionuclide therapy of cancer.
Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Malaria
Possible selection of host folate pathway gene polymorphisms in patients with malaria from a malaria endemic region in North East India.
Measles
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Meckel Diverticulum
Detection of a Meckel's diverticulum on PSMA PET/CT: A case report.
Melanoma
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors.
Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
Photodynamic Therapy of Melanoma B16 with Chlorin E6 Conjugated with a PSMA-Ligand.
Prostate-specific membrane antigen expression in melanoma metastases.
Memory Disorders
NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.
NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.
NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
Meningomyelocele
Role of parental folate pathway single nucleotide polymorphisms in altering the susceptibility to neural tube defects in South India.
Mesothelioma
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma.
Mesothelioma, Malignant
Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma.
Metabolic Syndrome
Dissecting the role of Folr1 and Folh1 genes in the pathogenesis of metabolic syndrome in spontaneously hypertensive rats.
Multiple Myeloma
Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.
Multiple Sclerosis
Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosis.
Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition.
Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.
Neoplasm Metastasis
(68)Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy.
68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
68-gallium Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Detects Rare Testicular Metastasis from Prostate Cancer.
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
68Ga-Prostate-Specific Membrane Antigen PET-Positive Paget Bone Disease With Metastatic Prostatic Carcinoma.
68Ga-Prostate-Specific Membrane Antigen PET/CT Uptake in Intraventricular Meningioma in the Choroid Plexus.
68Ga-Prostate-Specific Membrane Antigen-Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI.
68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy.
68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy.
68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.
A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients.
Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT.
Active Giant Cell Vasculitis Diagnosis with 68Ga PSMA PET/CT Imaging.
Advances in positron emission tomography applications for urologic cancers.
Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle.
Biochemical Recurrence of Prostate Cancer Presenting as Solitary Testicular Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography.
Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells.
Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Case Report: 18F-PSMA PET/CT May Improve the Clinical Management of Penile Metastases From Prostate Cancer.
Cerebellar Metastases From Prostate Cancer on 68Ga-PSMA PET/CT.
Circulating tumor cells mirror bone metastatic phenotype in prostate cancer.
Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer.
Cloning and characterization of the prostate-specific membrane antigen promoter.
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.
Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT.
Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma.
Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.
Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Correlations of 68Ga-PSMA PET/CT in the initial staging of prostate cancer patients.
Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review.
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
Diagnostic performance of
Diagnostic Performance of ??Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis.
Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer.
Early Detection of Bilateral Testicular Metastases From Prostatic Adenocarcinoma Using 68Ga-PSMA Ligand PET/CT.
Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes.
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.
Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.
Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT: Correlation Between Functional Imaging and Histology.
Herniated Thoracic Spleen Mimicking Lung Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in a Patient With Prostate Cancer.
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis.
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
Identification of a novel microsatellite marker tightly linked to the KAI-1 gene for predicting prostate cancer progression.
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?
Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?
Imaging for Metastasis in Prostate Cancer: A Review of the Literature.
Imaging of Prostate Cancer.
Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer.
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells.
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
Is 177Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis?
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer.
Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy.
Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy.
Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.
New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments.
Novel ?- and ?-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen.
Nuclear Medicine Imaging of Prostate Cancer.
Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Optimization of Labeling PSMA(HBED) with Ethanol-Postprocessed (68)Ga and Its Quality Control Systems.
Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Patterns of Lymph Node Failure in Patients With Recurrent Prostate Cancer Postradical Prostatectomy and Implications for Salvage Therapies.
Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection.
Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.
PET imaging in urology: a rapidly growing successful collaboration.
Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning.
Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).
ProstaScint(R) Scan: Contemporary Use in Clinical Practice.
Prostate Cancer Imaging with Novel PET Tracers.
Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection.
Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.
Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice.
Prostate-specific membrane antigen expression in melanoma metastases.
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond.
Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis.
Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis.
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.
Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.
Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.
PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma.
PSMA Theranostics: Current Status and Future Directions.
Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy.
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review.
Salvage surgery for nodal recurrent prostate cancer.
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (64Cu-PSMA PET/CT) in a patient with prostate cancer.
Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET.
Spinal Tuberculosis Mimicking as Prostate Cancer Metastases in Ga-68 Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography.
Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
Subacute Cerebellar Infarction With Uptake on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer.
Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-specific Membrane Antigen.
Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers.
Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
The emergence of radioimmunoscintigraphy for prostate cancer.
The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.
The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate.
The potential of PSMA-targeted alpha therapy in the management of prostate cancer.
The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.
The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy.
Unusual presentation of castrate-resistant prostate cancer with urethral and inguinal nodal metastasis.
Upcoming Role of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Detecting Occult Metastases in Prostate Cancer.
Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia.
Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Neoplasm Micrometastasis
(2S)-2-(3-(1-Carboxy-5-(4-[211At]astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-Targeted ?-Particle Radiopharmaceutical Therapy.
Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread.
Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.
Significance of micrometastases in prostate cancer.
The application of the RT-PCR method for the staging of the prostate cancer progression.
Neoplasms
(111)In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its (111)in-labelled murine antibody in the evaluation of prostate cancer.
(177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.
(64)Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer.
(68)Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging.
11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase).
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor.
18F-DCFPyL PET/CT in Oncocytoma.
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
18F-Labeled Small-Molecule and Low-Molecular-Weight PET Tracers for the Noninvasive Detection of Cancer.
33 increased sensitivity in the detection of circulating prostatic tumor cells in peripheral blood after immunobead enrichment and RT-PCR for prostate specific membrane antigen (PSMA) mRNA
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
68Ga-Prostate-Specific Membrane Antigen PET/CT in Cholangiocarcinoma: A Potential Biomarker for Targeted Radioligand Therapy?
68Ga-Prostate-Specific Membrane Antigen PET/CT in Sinonasal Glomangiopericytoma-Exploring Theranostic Avenues!
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future?
68Ga-PSMA PET/CT in the evaluation of locally advanced and metastatic breast cancer, a single center experience.
68Ga-PSMA PET/CT Scan on Postoperative Assessment of Sinonasal Glomangiopericytoma.
68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability.
68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study.
68Ga-PSMA-Ligand PET/CT Uptake in Anthracosilicosis.
99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention.
A case of hepatic focal nodular hyperplasia mimicking hepatocellular carcinoma identified on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography.
A Case of Well-differentiated Hepatocellular Carcinoma Identified on Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
A deformable multimodal image registration using PET/CT and TRUS for intraoperative focal prostate brachytherapy.
A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen.
A dimeric Peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
A Low Molecular Weight PSMA-Based Fluorescent Imaging Agent for Cancer.
A Novel Screening Method to Establish Tumor-targeting Antibodies Reliable for Drug Delivery System.
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors.
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma.
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.
A PSMA-targeted theranostic agent for photodynamic therapy.
A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.
A ribonucleoprotein octamer for targeted siRNA delivery.
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer.
Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging.
Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors.
Advancement of MR and PET/MR in Prostate Cancer.
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Advances in Targeted Alpha Therapy for Prostate Cancer.
An 89Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
An Anti-PSMA Bivalent Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Imaging and Therapy.
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.
An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay.
Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Analysis of prostate-specific membrane antigen splice variants in LNCap cells.
Androgen receptor overexpression in prostate cancer in type 2 diabetes.
Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle.
Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.
Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells.
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.
Aptamer:toxin conjugates that specifically target prostate tumor cells.
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature.
Biochemical characterization of human glutamate carboxypeptidase III.
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
Biosensing with Virus Electrode Hybrids.
Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators.
Bridging the Metabolic Parallels Between Neurological Diseases and Cancer.
Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.
Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase.
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture.
Chemically synthesized molecules with the targeting and effector functions of antibodies.
Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads.
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI(3)kinase/AKT/Bcl-X(L) Activation and CD8(+) T Cell-mediated Tumor Eradication.
Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
Clinical Molecular Imaging with Radiotracers: Current Status.
Clinical trials of cancer therapies targeting prostate-specific membrane antigen.
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
Clinical Utility of 68Ga-Prostate-Specific Membrane Antigen PET/CT Scan on Postoperative Assessment of Juvenile Nasal Angiofibroma.
Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.
Co-administration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growth.
Co-Delivery of Docetaxel and p44/42 MAPK siRNA Using PSMA Antibody-Conjugated BSA-PEI Layer-by-Layer Nanoparticles for Prostate Cancer Target Therapy.
Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute.
Combined impact of polymorphism of folate metabolism genes; glutamate carboxypeptidase, methylene tetrahydrofolate reductase and methionine synthase reductase on breast cancer susceptibility in kashmiri women.
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).
Comparative Findings Between 68Ga-PSMA and 18F-FDG PET/CT for Hepatocellular Carcinoma
Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA+ tumors in mice using 64Cu-radiolabeled monoclonal antibodies.
Comparison between 177Lu-iPSMA and 225Ac-iPSMA dosimetry at a cellular level in an animal bone metastasis model.
Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT.
Comparison of 68Ga-PSMA PET/CT and Contrast-Enhanced MRI on Residual Disease Assessment of Juvenile Nasal Angiofibroma.
Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml.
Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Comprehensive Evaluation of Prostate-Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.
Conformational and SAR analysis of NAALADase and PSMA inhibitors.
Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.
Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis.
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
Correlations of the 68Ga-PSMA PET/CT derived primary prostate tumor PSMA expression parameters and metastatic patterns in patients with Gleason Score >7 prostate cancer.
Correspondence re: Ghosh A and Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539, 2004.
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.
Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
Demonstration of 68Ga-prostate-specific Membrane Antigen Uptake in Metastatic Pancreatic Neuroendocrine Tumor.
Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.
Detection of minimal disease in patients with solid tumors.
Detection of Prostate Specific Membrane Antigen at Picomolar Levels Using Biocatalysis Coupled to Assisted Ion Transfer Voltammetry at a Liquid-Organogel Microinterface Array.
Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium.
Detection Rate of 68Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy.
Development and Screening of a Series of Antibody-Conjugated and Silica-Coated Iron Oxide Nanoparticles for Targeting the Prostate-Specific Membrane Antigen.
Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen.
Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Development of tumor-targeted near infrared probes for fluorescence guided surgery.
Diagnostic accuracy of 68 Ga-PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen.
Diagnostic performance of 18F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis.
Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study.
Diagnostic potential of serum extracellular vesicles expressing prostate-specific membrane antigen in urologic malignancies.
Differences in the expression of telomerase and prostate-specific membrane antigen in non-advanced prostatic cancer.
Different Appearances of 3 Malignancies in 68Ga-PSMA-11 Versus 18F-FDG PET/CT.
Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.
Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients.
Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages.
DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening.
Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts.
Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy.
Dynamic 68Ga-PSMA-11 PET/CT for the Primary Evaluation of Localized Renal Mass: A Prospective Study.
Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen.
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond.
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.
Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation.
Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs.
Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.
Enzymatic radiosynthesis of a 18F-Glu-Ureido-Lys ligand for the prostate-specific membrane antigen (PSMA).
Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization.
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT.
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Expression of glutamate carboxypeptidase II in human brain.
Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization.
Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade.
Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance.
Expression of prostate-specific membrane antigen in normal and malignant human tissues.
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.
Expression of prostate-specific membrane antigen in renal cortical tumors.
Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature.
Formulation and dosage of therapeutic nanosuspension for active targeting of docetaxel (WO 2014210485A1).
From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development.
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers.
Gastric Metastasis of Prostate Cancer as an Unusual Presentation Using 68Ga-Prostate-Specific Membrane Antigen PET/CT.
GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.
GCPII Imaging and Cancer.
GCPII Variants, Paralogs and Orthologs.
Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay.
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Glutamyl hydrolase. pharmacological role and enzymatic characterization.
Heterobivalent agents targeting PSMA and integrin-?v?3.
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
High expression of PSM-E correlated with tumor grade in prostate cancer: A new alternatively spliced variant of prostate-specific membrane antigen.
Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device.
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Imaging for Response Assessment in Cancer Clinical Trials.
Imaging of prostate cancer: optimizing affinity to prostate specific membrane antigen by spacer modifications in a tumor spheroid model.
Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Imaging of Prostate-Specific Membrane Antigen Using [(18)F]DCFPyL.
Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer.
Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.
Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors.
Improved Cancer Targeting by Multimerizing Aptamers on Nanoscaffolds.
Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.
In vitro and in vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-conjugated Antibody to Prostate-specific Membrane Antigen.
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
In Vivo Demonstration of PSMA Expression in Adenocarcinoma Urinary Bladder Using 68Ga-PSMA 11 PET/CT.
In vivo targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two ?-linked glutamate residues at the COOH terminus.
In Vivo Visualization of Prostate-Specific Membrane Antigen in Adenoid Cystic Carcinoma of the Salivary Gland.
Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer.
Incidental finding of ileal gastrointestinal stromal tumour during prostate cancer staging with prostate-specific membrane antigen scan.
Incidental Prostate-Specific Membrane Antigen Uptake in a Peripheral Nerve Sheath Tumor.
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
Induction of PSMA and Internalization of an anti-PSMA mAb in the Vascular Compartment.
Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.
Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles.
Initial Experience with Volumetric (68)Ga-PSMA I&T PET/CT for Assessment of Whole-body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
Introduction of Novel Structured Reporting Systems for PET Radiotracers with Potential Theranostic Applications.
Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain: [La ketamine et un inhibiteur N-acetylaspartylglutamate peptidase exercent une analgesie sur la douleur du cancer des os].
Lactate Dehydrogenase A Depletion Alters MyC-CaP Tumor Metabolism, Microenvironment, and CAR T Cell Therapy.
Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.
Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues.
Long-Circulating Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent.
Long-Term Stability Monitoring of Printed Proteins on Paper-Based Membranes.
Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging.
M13 phage-functionalized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescence imaging of targeted tumors.
MDM2 and PSMA Play Inhibitory Roles in Metastatic Breast Cancer Cells Through Regulation of Matrix Metalloproteinases.
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy-Do Different Software Solutions Deliver Comparable Results?
Metal-Based PSMA Radioligands.
Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy.
Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation.
Microfluidic-integrated patterned ITO immunosensor for rapid detection of prostate-specific membrane antigen biomarker in prostate cancer.
Missing Selectivity of Targeted 4?-Phorbol Prodrugs Expected to be Potential Chemotherapeutics.
Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands.
Molecular Imaging in Oncology Using Positron Emission Tomography.
Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.
Monoclonal antibodies and prostate-specific membrane antigen.
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.
Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer--focus on prostate-specific membrane antigen?
Monosodium glutamate reduces 68Ga-PSMA-11 uptake in salivary glands and kidneys in preclinical prostate cancer model.
More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy.
N-Substituted Glutamyl Sulfonamides as Inhibitors of Glutamate Carboxypeptidase II (GCP2).
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.
Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin.
Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues.
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.
Noninvasive Imaging of PSMA in Prostate Tumors with (89)Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives.
Novel 177Lu-labeled Albumin-binder-conjugated PSMA-targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-kidney Absorbed Dose Ratio.
Novel Non-Congeneric Derivatives of the Choline Kinase Alpha Inhibitor ICL-CCIC-0019.
Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer.
Nuclear Medicine Imaging of Prostate Cancer.
Nuclear Medicine Imaging Procedures in Oncology.
One-step 18F-labeling and preclinical evaluation of prostate specific membrane antigen trifluoroborate probes for cancer imaging.
Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection.
Peptide-Based Radiopharmaceuticals for Molecular Imaging of Prostate Cancer.
PET imaging in urology: a rapidly growing successful collaboration.
PET imaging quantifying 68Ga-PSMA-11 uptake in metastatic colorectal cancer.
PET/CT in the management of differentiated thyroid cancer.
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
Photodynamic Therapy Is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer.
Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour.
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.
Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
Positron-emission tomography imaging in urological oncology: Current aspects and developments.
Potential effective inhibitory compounds against Prostate Specific Membrane Antigen (PSMA): A molecular docking and molecular dynamics study.
Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness.
Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with
Pre-therapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC).
Preclinical assessment of 68 Ga-PSMA-617 entrapped in a microemulsion delivery system for applications in prostate cancer PET/CT imaging.
Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.
Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use.
Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).
Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.
Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.
Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis.
Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.
Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging.
Prostate Specific Membrane Antigen (PSMA) Regulates Angiogenesis Independently of VEGF during Ocular Neovascularization.
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.
Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy.
Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in Egyptian patients.
Prostate-Specific Membrane Antigen (PSMA) Promotes Angiogenesis of Glioblastoma Through Interacting With ITGB4 and Regulating NF-?B Signaling Pathway.
Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.
Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
Prostate-specific membrane antigen and its truncated form PSM'.
Prostate-specific membrane antigen and other prostatic tumor markers on the horizon.
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.
Prostate-specific membrane antigen as a target for cancer imaging and therapy.
Prostate-specific membrane antigen directed selective thrombotic infarction of tumors.
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging.
Prostate-Specific Membrane Antigen Expression in Neovasculature of Glioblastoma Multiforme.
Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
Prostate-specific membrane antigen expression in regeneration and repair.
Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond.
Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing?
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane.
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.
Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction.
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Prostate-specific Membrane Antigen-expressing Hepatic Lesion: Metastatic or Hepatocellular Carcinoma.
Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin.
Prostate-specific membrane antigen.
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma.
PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival.
PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68Ga-PSMA Ligand PET/CT.
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome.
PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression.
PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.
PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.
PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.
PSMA-targeted dendrimers: a patent evaluation (WO2012078534).
PSMA-targeted melanin-like nanoparticles as a multifunctional nanoplatform for prostate cancer theranostics.
PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.
Pulmonary Opacities and Bronchiectasis Avid on 68Ga-PSMA PET.
Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy.
Quantum dots for in vivo molecular and cellular imaging.
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Radiomics Analysis for 177Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer-A Model Based on Clinical Example.
Radiopharmaceutical Therapy.
Radium and other alpha emitters in prostate cancer.
Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028.
Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656-61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists.
Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. Lancet 2020;395:1208-16.
Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Lancet 2020;395:1208-16: PSMA Positron Emission Tomography: One Tracer Fixes Them All!
Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer.
Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.
Recent advances of bispecific antibodies in solid tumors.
Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells.
Rectal Carcinoma on 68Ga-PSMA PET/CT.
Recurrent Brain Metastasis of Triple Negative Breast Cancer With High Uptake in 68Ga-PSMA-11 PET/CT.
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Renal-type clear cell carcinoma of prostate: A case report and review of literature.
Repeatability of 68Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028: Despite its Slightly Limited Specificity, Prostate-specific Membrane Antigen Imaging is Still a Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy.
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.
Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: a feasibility study.
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).
Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays.
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
Small Molecule, Multimodal, [18F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study.
SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with Recurrent Prostate Cancer.
Structural and Biochemical Characterization of a Novel Aminopeptidase from Human Intestine.
Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer.
Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III.
Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors.
Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate.
Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.
Synthesis and Binding of a Novel PSMA-specific Conjugate.
Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.
Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of PSMA and Hypoxia for Prostate Cancer.
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).
Synthesis of modular dipeptide mimetics on the basis of diazabicycloalkanes and derivatives thereof with sulphur containing side chains.
Synthesis of Symmetrical Tetrameric Conjugates of the Radiolanthanide Chelator DOTPI for Application in Endoradiotherapy by Means of Click Chemistry.
Synthesis, chemical and biochemical characterization of Lu2O3-iPSMA nanoparticles activated by neutron irradiation.
T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.
Targeted ?-therapy in non-prostate malignancies.
Targeted ?-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen).
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Targeted Radiosensitizers for MR-Guided Radiation Therapy of Prostate Cancer.
Targeted, Activatable, In Vivo Fluorescence Imaging of Prostate-Specific Membrane Antigen (PSMA) Positive Tumors Using the Quenched Humanized J591 Antibody-Indocyanine Green (ICG) Conjugate.
Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers.
Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging.
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.
Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface?
Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Targeting thapsigargin towards tumors.
Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies.
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.
The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers.
The clinical role of prostate-specific membrane antigen (PSMA).
The effects of specific expression of apoptin under the control of PSES and PSA promoter on cell death and apoptosis of LNCaP cells.
The expression of prostate-specific membrane antigen in peripheral blood leukocytes.
The frequency of thyroid incidental findings and risk of malignancy detected by 68Ga-labeled prostate-specific membrane antigen PET/CT in prostate cancer.
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways.
The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.
The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Theranostics in oncology: What radiologists want to know.
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.
Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents.
Triple synchronous tumours of the urinary system with different histologies: a case report.
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?
Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer.
Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.
Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications.
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).
Use of oligonucleotide aptamer ligands to modulate the function of immune receptors.
Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.
Using RNA aptamers and the proximity ligation assay for the detection of cell surface antigens.
Vaccine therapy for prostate cancer.
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen-a Possible Novel Therapeutic Target.
What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer.
[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).
[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma.
[Clinical significance of detecting circulating cancer cells in patients with solid malignancies]
[Prostate specific membrane antigen (PSMA) as a role of tumor marker]
[Prostate-specific membrane antigen. A new sensitive molecular indicator in metastasizing prostatic cancer]
[Radionuclide therapy and diagnostics in urology].
[Related biomarkers in the diagnosis of prostate cancer].
[Reports of prostate needle biopsies-what pathologists provide and urologists want].
[Significance of current bio- and molecular-markers in urological cancers]
Neoplasms, Germ Cell and Embryonal
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Neoplasms, Glandular and Epithelial
68Ga-PSMA-Ligand PET/CT Uptake in Anthracosilicosis.
Neoplasms, Second Primary
Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT: Correlation Between Functional Imaging and Histology.
Neoplastic Cells, Circulating
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Microfluidic-integrated patterned ITO immunosensor for rapid detection of prostate-specific membrane antigen biomarker in prostate cancer.
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy.
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
[Clinical significance of detecting circulating cancer cells in patients with solid malignancies]
Nerve Sheath Neoplasms
Incidental Prostate-Specific Membrane Antigen Uptake in a Peripheral Nerve Sheath Tumor.
Nervous System Diseases
Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Design of NAALADase inhibitors: a novel neuroprotective strategy.
Development of a High-Throughput Fluorescence Polarization Assay to Identify Novel Ligands of Glutamate Carboxypeptidase II.
Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer.
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.
Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
N-Substituted Glutamyl Sulfonamides as Inhibitors of Glutamate Carboxypeptidase II (GCP2).
NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.
Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism.
Progress in the discovery and development of glutamate carboxypeptidase II inhibitors.
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.
Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors.
Unprecedented Binding Mode of Hydroxamate-Based Inhibitors of Glutamate Carboxypeptidase II: Structural Characterization and Biological Activity.
Neural Tube Defects
Association of FOLH1, DHFR, and MTHFR gene polymorphisms with susceptibility of Neural Tube Defects: A case control study from Eastern India.
Glutamate carboxypeptidase II gene polymorphisms and neural tube defects in a high-risk Chinese population.
The H475Y polymorphism in the glutamate carboxypeptidase II gene increases plasma folate without affecting the risk for neural tube defects in humans.
The maternal folate hydrolase gene polymorphism is associated with neural tube defects in a high-risk Chinese population.
Neuralgia
Discovery of a para-Acetoxy-benzyl Ester Prodrug of a Hydroxamate-Based Glutamate Carboxypeptidase II Inhibitor as Oral Therapy for Neuropathic Pain.
Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain.
Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.
N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
ORALLY ACTIVE GCPII INHIBITOR, E2072, EXHIBITS SUSTAINED NERVE EXPOSURE AND ATTENUATES PERIPHERAL NEUROPATHY.
Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism.
Reversible Disulfide Formation of the GCP-II Inhibitor E2072 Results in Prolonged Systemic Exposures In Vivo.
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.
Neurilemmoma
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer.
Prostate-Specific Membrane Antigen PET/CT Incidental Finding of a Schwannoma.
Neurodegenerative Diseases
Design and pharmacological activity of phosphinic acid based NAALADase inhibitors.
Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity.
Neuroendocrine Tumors
An Impressive Approach in Nuclear Medicine: Theranostics.
Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
Exciting Opportunities in Nuclear Medicine Imaging and Therapy.
Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.
Phosphinic Acid Functionalized Polyazacycloalkane Chelators for Radiodiagnostics and Radiotherapeutics: Unique Characteristics and Applications.
Prostate-Specific Membrane Antigen (PSMA) Avid Pancreatic Neuroendocrine Tumor.
Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.
The emerging value of 64Cu for molecular imaging and therapy.
Neurofibromatoses
Increased Prostate-Specific Membrane Antigen Uptake in Neurofibromatosis.
Obesity
Gene expression profile of peripheral blood mononuclear cells in mild to moderate obesity in dogs.
Osteosarcoma
Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma.
Pancreatic Neoplasms
Prostate-specific membrane antigen as a marker of pancreatic cancer cells.
Peripheral Nervous System Diseases
Design and pharmacological activity of phosphinic acid based NAALADase inhibitors.
Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.
Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury.
ORALLY ACTIVE GCPII INHIBITOR, E2072, EXHIBITS SUSTAINED NERVE EXPOSURE AND ATTENUATES PERIPHERAL NEUROPATHY.
Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders.
Reversible Disulfide Formation of the GCP-II Inhibitor E2072 Results in Prolonged Systemic Exposures In Vivo.
The Role of Glutamate in Diabetic and in Chemotherapy Induced Peripheral Neuropathies and its Regulation by Glutamate Carboxypeptidase II.
Pheochromocytoma
68Ga-Labeled Prostate-Specific Membrane Antigen Uptake in Pheochromocytoma: An Incidental Finding in PET/CT Scan.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Incidental Finding of Acute Lymphocytic Leukemia in a Prostate-Specific Membrane Antigen PET/CT.
Priapism
Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Prostatic Hyperplasia
Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Monoclonal antibodies and prostate-specific membrane antigen.
The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma.
Prostatic Intraepithelial Neoplasia
Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
'Image and treat': an individualized approach to urological tumors.
(111)In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its (111)in-labelled murine antibody in the evaluation of prostate cancer.
(177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.
(177)Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.
(2S)-2-(3-(1-Carboxy-5-(4-[211At]astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-Targeted ?-Particle Radiopharmaceutical Therapy.
(64)Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer.
(68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
(68)Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions?
(68)Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
(68)Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.
(68)Ga-PSMA PET/CT in prostate cancer.
(68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer.
(68)Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with (223)Ra: Proof of Concept.
(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.
(68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy.
(99m)Tc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients.
11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase).
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy.
177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney.
18 F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer.
18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.
18F-DCFPyL PET/CT Imaging in Patients with Biochemical Recurrence Prostate Cancer after Primary Local Therapy.
18F-DCFPyL PET/CT in a Single Large Metastasis With Prostate-Specific Antigen Level of 856 ng/mL.
18F-DCFPyL PET/CT in Oncocytoma.
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.
18F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy.
1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer.
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.
225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient.
3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray.
64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer.
68 Ga-prostate-specific membrane antigen tracers can alter the management of more than half of prostate cancer patients with biochemical recurrence.
68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.
68-gallium Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Detects Rare Testicular Metastasis from Prostate Cancer.
68Ga Prostate-specific Membrane Antigen PET/CT for Primary Diagnosis of Prostate Cancer: Complementary or Alternative to Multiparametric MR Imaging.
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.
68Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent.
68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies: Has the Time Come to Remove "PS" From PSMA?
68Ga-Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer: A Case Report.
68Ga-Prostate-Specific Membrane Antigen PET/CT in Triple-Negative Breast Cancer.
68Ga-Prostate-Specific Membrane Antigen PET/CT Uptake in Intraventricular Meningioma in the Choroid Plexus.
68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.
68Ga-Prostate-Specific Membrane Antigen-Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI.
68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.
68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients.
68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy.
68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future?
68Ga-PSMA PET/CT Imaging and 153Sm-EDTMP Bone Pain Palliation Therapy.
68Ga-PSMA PET/CT Imaging in Multiple Myeloma.
68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?
68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.
68Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis.
68Ga-PSMA Uptake in Middle Lobe Syndrome.
68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.
68Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer.
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability.
68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients' disease management and adequacy of impact.
68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue.
68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer.
68Ga-PSMA-I&T-PET/CT interobserver and intraobserver agreement for prostate cancer: a lesion based and subregional comparison study among observers with different levels of experience.
68Ga-PSMA-Ligand PET/CT Uptake in Anthracosilicosis.
68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial.
68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer.
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
??Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
?Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma.
A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.
A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention.
A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models.
A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.
A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer: The Results of 2 Prospective, Multicenter Trials.
A designer bow-tie combination therapeutic platform: An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation.
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.
A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
A Highly Specific Multiple Enhancement Theranostic Nanoprobe for PET/MRI/PAI Image-Guided Radioisotope Combined Photothermal Therapy in Prostate Cancer.
A Low Molecular Weight PSMA-Based Fluorescent Imaging Agent for Cancer.
A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer.
A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA).
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen.
A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging.
A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
A pharmacoeconomic evaluation of staging modalities for patients with newly diagnosed and occult recurrent adenocarcinoma of the prostate.
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma.
A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.
A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.
A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
A PSMA-targeted theranostic agent for photodynamic therapy.
A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy.
A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.
A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.
A Retrospective Analysis of the Safety and Activity of Lutetium-177-PSMA Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
A ribonucleoprotein octamer for targeted siRNA delivery.
A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer.
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
A Structure-Activity Relationship Study of Bimodal BODIPY-Labeled PSMA-Targeting Bioconjugates.
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer.
A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?
Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes.
Active Giant Cell Vasculitis Diagnosis with 68Ga PSMA PET/CT Imaging.
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Adding prostate-specific membrane antigen positron emission tomography (PSMA PET) to our prostate cancer armamentarium raises many questions.
Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
Advancement of MR and PET/MR in Prostate Cancer.
Advances in positron emission tomography applications for urologic cancers.
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Advances in prostate cancer.
Advances in prostate-specific membrane antigen PET of prostate cancer.
Advances in PSMA-targeted therapy for prostate cancer.
Advances in Targeted Alpha Therapy for Prostate Cancer.
Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617.
Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding.
Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.
An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells.
An Impressive Approach in Nuclear Medicine: Theranostics.
An improved 211At-labeled agent for PSMA-targeted alpha therapy.
An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands.
An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay.
An ultrasound-responsive dual-modal US/T1 -MRI contrast agent for potential diagnosis of prostate cancer.
Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Analysis of prostate-specific membrane antigen splice variants in LNCap cells.
Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer.
Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Anti-PSMA monoclonal antibody increases the toxicity of paclitaxel carried by carbon nanotubes.
Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation.
Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics.
Antibody-drug conjugates targeting prostate-specific membrane antigen.
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.
Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer.
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.
Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey.
Assessing Response to [177Lu]PSMA Radioligand Therapy using modified PSMA PET Progression Criteria.
Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
Association of glutamate carboxypeptidase II (GCPII) haplotypes with breast and prostate cancer risk.
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer.
Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
Automated radiosynthesis of [68 Ga]Ga-PSMA-11 and [177 Lu]Lu-PSMA-617 on the iPHASE MultiSyn module for clinical applications.
Automated synthesis module and sterile cold kit for 68Ga-PSMA-11 do not show differences in PET/CT image quality.
Automated synthesis of 68 Ga/177 Lu-PSMA on the Trasis miniAllinOne.
Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models.
Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions.
Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination.
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.
Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation.
Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.
Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging.
Biochemical Recurrence of Prostate Cancer Presenting as Solitary Testicular Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography.
Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells.
Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells.
Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges.
Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
Biomarkers in Prostate-Specific Membrane Antigen Theranostics.
Biorecognition and Subcellular Trafficking of HPMA Copolymer-Anti-PSMA Antibody Conjugates by Prostate Cancer Cells.
Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.
Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells.
Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer.
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.
Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis.
Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence - a narrative review of literature.
Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer.
Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
Camel heavy chain antibodies against prostate-specific membrane antigen.
Can 68Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?
Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?
Can Gallium-68 Prostate-specific Membrane Antigen Ligand be a Potential Radiotracer for Renal Cortical Positron Emission Tomography Imaging?
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.
Cancer immunotherapy for prostate cancer.
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.
Cartography-based quality control of prostate cancer care: a necessary ground to targeted focal therapy.
Cell Membrane-Inspired Polymeric Vesicles for Combined Photothermal and Photodynamic Prostate Cancer Therapy.
Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer.
Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer.
Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
Cerebellar Metastases From Prostate Cancer on 68Ga-PSMA PET/CT.
Changes in gene expression and targets for therapy.
Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture.
Characterization of prostate cancer cell progression in zebrafish xenograft model.
Characterization of the enzymatic activity of PSM: comparison with brain NAALADase.
Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.
Chemically synthesized molecules with the targeting and effector functions of antibodies.
Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads.
Chemoprevention of Bladder and Prostate Carcinoma.
Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation.
Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer.
Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction.
Clinical Impact of Lower-Limb Imaging in 68Ga-PSMA PET/CT for Patients with Prostate Cancer.
Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities.
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy.
Clinical outcomes of 177Lu-PSMA radioligand therapy in taxane chemotherapy pretreated and taxane chemotherapy naïve patients with metastatic castration resistant prostate cancer.
Clinical parameters and nomograms for predicting lymph node metastasis detected with 68 Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
Clinical PET/MR.
Clinical translation of a PSMA inhibitor for (99m)Tc-based SPECT.
Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer.
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.
Clinical trials of cancer therapies targeting prostate-specific membrane antigen.
Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
Cloning and characterization of canine prostate-specific membrane antigen.
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase.
Combination of Forced Diuresis with Additional Late Imaging in 68Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake.
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy.
Combined Application of Albumin-Binding [177Lu]Lu-PSMA-ALB-56 and Fast-Cleared PSMA Inhibitors: Optimization of the Pharmacokinetics.
Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate Cancer.
Combined model-based and patient-specific dosimetry for
Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology.
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.
Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.
Comparison of planar, PET and well-counter measurements of total tumor radioactivity in a mouse xenograft model.
Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy.
Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents.
Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.
Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.
Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma.
Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.
Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality.
Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples.
Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement.
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177 Lu-PSMA-617 in LNCaP cells.
Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Conformational and SAR analysis of NAALADase and PSMA inhibitors.
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.
Constitutive and antibody-induced internalization of prostate-specific membrane antigen.
Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer.
Convenient Preparation of [(68)Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy.
Correction to: Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.
Correction: Identification and Characterization of Nuclease-Stabilized RNA Molecules That Bind Human Prostate Cancer Cells via the Prostate-Specific Membrane Antigen.
Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.
Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.
Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer.
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
Correlations of 68Ga-PSMA PET/CT in the initial staging of prostate cancer patients.
Correlations of the 68Ga-PSMA PET/CT derived primary prostate tumor PSMA expression parameters and metastatic patterns in patients with Gleason Score >7 prostate cancer.
Correspondence re: Ghosh A and Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539, 2004.
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer.
Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.
Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Current status of PSMA PET imaging in prostate cancer.
Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov.
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.
Current status of theranostics in prostate cancer.
Current use of PSMA-PET in prostate cancer management.
Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.
Day-to-day variability of [68Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation.
Dedicated Verification of an Accessory Parotid Gland via Minimal-Activity PSMA-PET/CT.
Dendritic cell-based immunotherapy of prostate cancer.
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis.
Design and synthesis of a novel BODIPY-labeled PSMA inhibitor.
Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.
Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II.
Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors.
Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens.
Detection and quantitation of glutamate carboxypeptidase II in human blood.
Detection efficacy of 18F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy.
Detection of a Meckel's diverticulum on PSMA PET/CT: A case report.
Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade.
Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate-specific membrane antigen.
Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007.
Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium.
Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy.
Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis.
Detection Rate of 68Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy.
Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
Detection rates of recurrent prostate cancer: 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review.
Development and Screening of a Series of Antibody-Conjugated and Silica-Coated Iron Oxide Nanoparticles for Targeting the Prostate-Specific Membrane Antigen.
Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer.
Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen.
Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution.
Development of a High-Throughput Fluorescence Polarization Assay to Identify Novel Ligands of Glutamate Carboxypeptidase II.
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Development of a Single Stranded DNA Aptamer as a Molecular Probe for LNCap Cells Using Cell-SELEX.
Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients.
Development of an Albumin-Based PSMA Probe With Prolonged Half-Life.
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [177Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome.
Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition.
Development of polymeric microbubbles targeted to prostate-specific membrane antigen as prototype of novel ultrasound contrast agents.
Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors.
Development of targeted near-infrared imaging agents for prostate cancer.
Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Diagnostic Accuracy of (64)Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.
Diagnostic accuracy of 18F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence.
Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.
Diagnostic accuracy of 68 Ga-PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen.
Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.
Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.
Diagnostic performance of
Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer.
Diagnostic Performance of 68Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer.
Diagnostic Performance of ??Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis.
Diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography in intermediate and high risk prostate cancer.
Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study.
Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review.
Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
Differences in the expression of telomerase and prostate-specific membrane antigen in non-advanced prostatic cancer.
Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for FDG imaging of PSMA-suppressed tumors.
Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients.
Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen.
Dipeptide inhibitors of the prostate specific membrane antigen (PSMA): A comparison of urea and thiourea derivatives.
Discovery of 18F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions.
Discovery of PSMA-specific peptide ligands for targeted drug delivery.
Discrepancy between Multiparametric Magnetic Resonance Imaging and 68Ga Prostate-Specific Membrane Antigen Positron Emission Tomography: A Simultaneous Acquired Positron Emission Tomography-Magnetic Resonance Imaging Case.
Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen.
DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer.
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Does lymph node localization affect prostate-specific membrane antigen uptake?
Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer.
Dual-labeled prostate-specific membrane antigen (PSMA)-targeting agent for preoperative molecular imaging and fluorescence-guided surgery for prostate cancer.
Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review.
DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting.
Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions.
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).
Early dynamic imaging in (68)Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.
Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer.
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).
Editorial Comment to Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?
Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen.
Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
Effect of external cooling on Lu-177 PSMA uptake for parotid glands.
Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer.
Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists.
Effective targeting of prostate cancer by lymphocytes redirected by a PSMA?×?CD3 bispecific single-chain diabody.
Effects of 225Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis.
Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes.
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-? Insensitive Genetically Targeted CD8
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients.
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.
Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia - A prospective study.
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer.
Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond.
Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.
Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.
Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.
Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization.
Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Enzymatic radiosynthesis of a 18F-Glu-Ureido-Lys ligand for the prostate-specific membrane antigen (PSMA).
Erratum: Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: Systematic Review and Network Meta-Analysis.
Establishing (177)Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer.
Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada.
Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study.
EV-Ident: Identifying Tumor-Specific Extracellular Vesicles by Size Fractionation and Single-Vesicle Analysis.
Evaluating a Machine Learning Tool for the Classification of Pathological Uptake in Whole-Body PSMA-PET-CT Scans.
Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis.
Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
Evaluation of Hybrid ??Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides.
Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer.
Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer.
Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer.
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Evolution of Peptide-Based Prostate-Specific Membrane Antigen (PSMA) Inhibitors: An Approach to Novel Prostate Cancer Therapeutics.
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis.
Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Exciting Opportunities in Nuclear Medicine Imaging and Therapy.
Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen.
Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer.
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3.
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.
Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid.
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma.
Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.
Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient.
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received 177Lu PSMA I&T therapy.
False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography.
Fibrous dysplasia as a possible false-positive finding in 68Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography study in the follow-up of prostate cancer.
Fine-tuning of the automated [18 F]PSMA-1007 radiosynthesis.
First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer.
First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer.
First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer.
Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
Flow cytometric detection of prostate tumor cells using chemoaffinity labels.
Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls.
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Fluorodeoxyglucose, sodium fluoride, and prostate-specific membrane antigen positron emission tomography studies for treatment response assessment in prostate cancer.
Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature.
Folic acid on iron oxide nanoparticles: platform with high potential for simultaneous targeting, MRI detection and hyperthermia treatment of lymph node metastases of prostate cancer.
Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.
Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides.
Follow-Up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells.
Functionalized NIR-II Semiconducting Polymer Nanoparticles for Single-cell to Whole-Organ Imaging of PSMA-Positive Prostate Cancer.
Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Gallium-68 prostate-specific membrane antigen PET-CT and the clinical management of prostate cancer.
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer.
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer.
Gallium-68 PSMA uptake in adrenal adenoma.
Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT: Correlation Between Functional Imaging and Histology.
Gastric Metastasis of Prostate Cancer as an Unusual Presentation Using 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Gastrin-Releasing Peptide Receptor in Low Grade Prostate Cancer: Can It Be a Better Predictor Than Prostate-Specific Membrane Antigen?
GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD.
GCPII Variants, Paralogs and Orthologs.
Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted ?-particle therapy.
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Global experience with PSMA-based alpha therapy in prostate cancer.
Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.
Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer.
Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.
Growth and characterization of LNCaP prostate cancer cell spheroids.
Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.
Head- to head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard.
Healing Sacral Fracture Masquerading as Metastatic Bone Disease on a 68Ga-PSMA PET/CT.
Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer.
Hemangioblastoma: An Unsuspected Pitfall in PSMA PET/CT.
Herniated Thoracic Spleen Mimicking Lung Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in a Patient With Prostate Cancer.
Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model.
Heterogeneous 68Ga-Prostate-Specific Membrane Antigen Uptake in the Left Upper Abdomen: Mesenchymal Tumor.
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer.
High 18Fluor-DCFPyL Uptake in Adrenal Adenomas.
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.
High expression of PSM-E correlated with tumor grade in prostate cancer: A new alternatively spliced variant of prostate-specific membrane antigen.
High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer.
High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA.
High-Throughput Electrochemical Microfluidic Immunoarray for Multiplexed Detection of Cancer Biomarker Proteins.
Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device.
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker.
Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
Home tests for prostate-specific membrane antigen being developed for prostate cancer diagnosis.
Hong Kong Urological Association-Hong Kong Society of Uro-Oncology consensus statements on the management of advanced prostate cancer-2019 Updates.
How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations?
Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.
Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen - Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction.
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.
Identification of a novel microsatellite marker tightly linked to the KAI-1 gene for predicting prostate cancer progression.
Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Identification of an antibody fragment specific for androgen-dependent prostate cancer cells.
Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.
Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617.
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.
Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?
Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted ?-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Imaging for Prostate Cancer Recurrence.
Imaging of Non-Prostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms.
Imaging of Prostate Cancer Using (64)Cu-Labeled Prostate-Specific Membrane Antigen Ligand.
Imaging of Prostate Cancer.
Imaging of prostate cancer: optimizing affinity to prostate specific membrane antigen by spacer modifications in a tumor spheroid model.
Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
Imaging of Prostate-Specific Membrane Antigen Using [(18)F]DCFPyL.
Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.
Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.
Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer.
Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging.
Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.
Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET.
Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors.
Immunohistochemical validation of PSMA-expression measured by (68)Ga-PSMA PET/CT in primary prostate cancer.
Immunotherapy for prostate cancer.
Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
Impact of 68Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.
Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single Center Study.
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model.
Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions of 68Ga-PSMA PET/CT Scans.
Implications of a new element in the early diagnostic pathway for prostate cancer for rural Australians.
Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer.
Improved oncological outcome after radical prostatectomy in patients staged with 68Ga-PSMA-11 PET: a single-center retrospective cohort comparison.
Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology.
Improving 68-Ga-PSMA PET/MR hybrid imaging of the prostate with un-renormalized absolute scatter correction.
Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA.
In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
In vitro and in vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-conjugated Antibody to Prostate-specific Membrane Antigen.
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.
In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles.
In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile.
In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma.
Incidental 68Ga-Prostate-Specific Membrane Antigen Uptake in Compression Fracture of a Vertebral Body.
Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate Cancer.
Incidental Detection of Hypothyroidism on 68Ga-PSMA-HBED-CC PET/CT Imaging.
Incidental Detection of Pleomorphic Sarcoma on 68Ga-PSMA PET/CT in a Patient With Prostate Cancer.
Incidental detection of primary hepatocellular carcinoma on 18F-prostate-specific membrane antigen-1007 positron emission tomography/computed tomography imaging in a patient with prostate cancer: A case report.
Incidental Detection of Tracer Avidity in Liposarcoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.
Incidental Detection of Type B2 Thymoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT Imaging.
Incidental finding of ileal gastrointestinal stromal tumour during prostate cancer staging with prostate-specific membrane antigen scan.
Incidental Malignancies identified during staging for Prostate Cancer with (68)Ga -PSMA HBED-CC PET imaging.
Incidental Metastatic Melanoma Identified on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer.
Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective.
Increased PSMA Expression in Castration-Resistant Prostate Cancer Metastases 3 Months After Initiation of Enzalutamide Indicated by 18F-DCFPyL PET/CT.
Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector.
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
Inflammatory bowel disease and prostate cancer risk: A systematic review.
Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.
Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.
Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles.
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Initial evaluation of PET/CT with 18 F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients.
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.
Initial multicentre experience of (68) gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.
Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.
Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer.
Intraobserver and interobserver agreement for the interpretation of 68Ga-prostate-specific membrane antigen-I&T positron emission tomography/computed tomography imaging.
Introduction of Novel Structured Reporting Systems for PET Radiotracers with Potential Theranostic Applications.
Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI.
Is 177Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis?
Is prostate-specific membrane antigen a multifunctional protein?
Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
Isolated aplasia of submandibular salivary gland and contralateral prominence of submandibular and sublingual salivary glands incidentally found on 68Ga-prostate-specific membrane antigen positron emission tomography-computed tomography.
Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen.
Juvenile Nasal Angiofibroma on 68Ga-PSMA PET/CT: Opening New Frontiers.
Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents.
Kidney doses in 177Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients.
Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy.
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer.
Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.
Lesion Detection and Interobserver Agreement with Advanced Image-Reconstructions for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer.
Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues.
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors.
Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence.
Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.
Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
Long-Circulating Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent.
Long-range two-photon scattering spectroscopy ruler for screening prostate cancer cells.
Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
Love Wave Sensor for Prostate-Specific Membrane Antigen Detection Based on Hydrophilic Molecularly-Imprinted Polymer.
Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging.
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry.
Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.
Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Lymph Node Assessment in Prostate Cancer: Evaluation of Iodine Quantification With Spectral Detector CT in Correlation to PSMA PET/CT.
Lymphangitic Carcinomatosis From Prostate Cancer Identified With Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography Imaging.
Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy.
Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer.
Magnetic polymeric nanobubbles with optimized core size for MRI/ultrasound bimodal molecular imaging of prostate cancer.
Management of positive lymph nodes following radical prostatectomy.
Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer.
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity.
Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy-Do Different Software Solutions Deliver Comparable Results?
Metal-Based PSMA Radioligands.
Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy.
Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness.
Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation.
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or….
Methylation state of the prostate specific membrane antigen (PSMA) CpG island in prostate cancer cell lines.
Microfluidic-integrated patterned ITO immunosensor for rapid detection of prostate-specific membrane antigen biomarker in prostate cancer.
Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.
Modular Synthesis of DOTA-Metal-Based PSMA-Targeted Imaging Agents for MRI and PET of Prostate Cancer.
Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer.
Molecular determination of surgical margins using fossa biopsies at radical prostatectomy.
Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
Molecular Imaging of Prostate Cancer.
Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer.
Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer.
Monoclonal antibodies and prostate-specific membrane antigen.
More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.
More than the prostate: Intrapancreatic accessory spleen and papillary thyroid cancer detected with 18F-PSMA PET/CT.
Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview.
Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII.
Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides.
Multi-component Polymeric System for Tumour Cell-Specific Gene Delivery Using a Universal Bungarotoxin Linker.
Multi-Modal PET and MR Imaging in the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial in Vivo Testing of Target-Specific Radioligands.
Multianalyte quantitative competitive PCR on optically encoded microspheres for an eight-gene panel related to prostate cancer.
Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging.
Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer.
Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative.
Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting.
Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.
N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy.
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.
Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.
Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression.
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody.
New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells.
New circulating biomarkers for prostate cancer.
New frontiers in focal therapy for prostate cancer: Prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging.
New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.
New Imaging Techniques in Prostate Cancer.
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.
New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments.
Next revolution in molecular theranostics: personalized medicine for urologic cancers.
NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Non-prostate uptake on 18F-PSMA-1007 PET/CT: a case of myeloma.
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
Nonspecific Uptake of 68Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature.
Novel ?- and ?-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen.
Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer.
Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
Novel multifunctional 18F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties.
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.
Novel prostate-specific promoter derived from PSA and PSMA enhancers.
Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.
Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography.
Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
Oligometastatic prostate cancer: Metastases-directed therapy?
One-pot synthesis of carbon dots with intrinsic folic acid for synergistic imaging-guided photothermal therapy of prostate cancer cells.
One-step 18F-labeling and preclinical evaluation of prostate specific membrane antigen trifluoroborate probes for cancer imaging.
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer.
Optimization of Labeling PSMA(HBED) with Ethanol-Postprocessed (68)Ga and Its Quality Control Systems.
Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer.
Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
Other biomarkers for detecting prostate cancer.
Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.
Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy.
Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.
Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.
Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A population-based analysis.
Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer.
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells.
Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.
Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.
Perineum and penile invasion of recurrent prostate carcinoma shown by Ga-68 PSMA PET/CT.
PET imaging in prostate cancer: focus on prostate-specific membrane antigen.
PET imaging in urology: a rapidly growing successful collaboration.
PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer.
PET/CT imaging of prostate cancer in the era of small molecule prostate specific membrane antigen targeted tracers.
Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
Phase 2 study of (99m)Tc-trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic lymph node dissection.
Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer.
Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).
Phosphinic Acid Functionalized Polyazacycloalkane Chelators for Radiodiagnostics and Radiotherapeutics: Unique Characteristics and Applications.
Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.
Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT.
Pitfalls in Gallium-68 PSMA PET/CT Interpretation-A Pictorial Review.
Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells.
Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy.
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer.
Polymeric nanoparticles for drug delivery.
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.
Positive Multifocal PSMA PET/CT in a Patient With Prostate Cancer and Follicular Lymphoma.
Positron emission tomography (PET) radiotracers for prostate cancer imaging.
Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer.
Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?
Positron-emission tomography imaging in urological oncology: Current aspects and developments.
Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.
Potential of radiolabelled PSMA PET/CT or PET/MRI diagnostic procedures in gliomas/glioblastomas.
Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness.
Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Preclinical evaluation and pilot clinical study of Al18F-PSMA-BCH for prostate cancer imaging.
Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer.
Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer.
Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer.
Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for 64Cu/67Cu-Based Theranostics in Prostate Cancer.
Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.
Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer.
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.
Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer.
Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [
Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.
Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer.
Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).
Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer.
Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.
Procedures for the GMP-Compliant Production and Quality Control of [
Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy.
Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy.
Prognostic importance of PSA response in patients who received Lutetium-177 PSMA treatment for castration resistant prostate cancer.
Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells.
Prospective Evaluation of 18F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI.
Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis.
Prospective Validation of Gallium-68 PSMA-PET/CT in Primary Staging of Prostate Cancer Patients.
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
ProstaScint(R) Scan: Contemporary Use in Clinical Practice.
Prostate cancer cells show a nearly 100-fold increase in the expression of the longer of two alternatively spliced mRNAs of the prostate-specific membrane antigen (PSM)
Prostate Cancer Imaging with Novel PET Tracers.
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.
Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection.
Prostate cancer PET tracers: essentials for the urologist.
Prostate Cancer Targeted X-Ray Fluorescence Imaging via Gold Nanoparticles Functionalized With Prostate-Specific Membrane Antigen (PSMA).
Prostate cancer targeting motifs: Expression of ?(?) ?(3) , neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts.
Prostate cancer vaccines: current status and future potential.
Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
Prostate penile metastasis: Incidence and imaging pattern on 68 Ga-PSMA PET/CT.
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.
Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread.
Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?
Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro.
Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.
Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.
Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro.
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy.
Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.
Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
Prostate Specific Membrane Antigen Targeted (18)F-DCFPyL Positron Emission Tomography/Computerized Tomography in the Preoperative Staging of Men with High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.
Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.
Prostate specific membrane antigen: the role in salvage lymph node dissection and radio-ligand therapy.
Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase.
Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Prostate-specific antigen and new related markers for prostate cancer.
Prostate-specific membrane antigen (FOLH1): recent advances in characterising this putative prostate cancer gene.
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo".
Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells.
Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck.
Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review.
Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer.
Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.
Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer.
Prostate-specific membrane antigen (PSMA): current benefits and future value.
Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema.
Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
Prostate-specific membrane antigen and its truncated form PSM'.
Prostate-specific membrane antigen as a target for cancer imaging and therapy.
Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability.
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity.
Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer.
Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.
Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice.
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Prostate-specific membrane antigen expression in melanoma metastases.
Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
Prostate-Specific Membrane Antigen Expression in Primary Juvenile Nasal Angiofibroma-A Pilot Study.
Prostate-specific membrane antigen expression in the duodenum: implications in coeliac disease and immunotherapy for prostate cancer.
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.
Prostate-specific membrane antigen expression predicts prostate cancer recurrence.
Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Prostate-specific membrane antigen for the surgical oncologist: interpreting expression beyond the prostate.
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Prostate-specific Membrane Antigen Imaging and Theranostics Impact Patient Outcomes.
Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond.
Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.
Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis.
Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges.
Prostate-specific Membrane Antigen PET in Prostate Cancer.
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy.
Prostate-specific membrane antigen PET/MRI validation of MR textural analysis for detection of transition zone prostate cancer.
Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer.
Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis.
Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy.
Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.
Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Prostate-specific Membrane Antigen Positron Emission Tomography-guided Radiotherapy.
Prostate-Specific Membrane Antigen Positron Emission Tomography-Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy.
Prostate-specific membrane antigen positron emission tomography/computed tomography combined with sentinel node biopsy for primary lymph node staging in prostate cancer.
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Locally Advanced, Recurrent, and Metastatic Prostate Cancer.
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.
Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer.
Prostate-specific membrane antigen radioligand therapy of prostate cancer.
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles?
Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand.
Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence.
Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide.
Prostate-Specific Membrane Antigen Targeted Polymersomes for Delivering Mocetinostat and Docetaxel to Prostate Cancer Cell Spheroids.
Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility.
Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option.
Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.
Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer.
Prostate-specific membrane antigen-derived primers in a nested reverse transcription polymerase chain reaction for detecting prostatic cancer cells.
Prostate-Specific Membrane Antigen-Guided Surgery.
Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer.
Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells.
Prostate-specific membrane antigen-targeted photoacoustic imaging of prostate cancer in vivo.
Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption.
Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives.
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Prostate-Specific Membrane Antigen: Much More Than a Prostate Cancer Marker.
Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.
Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice.
Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma.
PSA targeted dual-modality manganese oxide-mesoporous silica nanoparticles for prostate cancer imaging.
PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
PSA-stratified performance of 18F- and 68Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer.
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
PSMA Antibody-Conjugated Pentablock Copolymer Nanomicellar Formulation for Targeted Delivery to Prostate Cancer.
PSMA brings new flavors to PI3K signaling: A role for glutamate in prostate cancer.
PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.
PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?
PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool.
PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68Ga-PSMA Ligand PET/CT.
PSMA expression is highly homogenous in primary prostate cancer.
PSMA ligands in prostate cancer - Probe optimization and theranostic applications.
PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response.
PSMA PET/CT and staging high risk prostate cancer: a non-systematic review of high clinical impact literature.
PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.
PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.
PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
PSMA Theranostics: A "Must Have" in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature.
PSMA Theranostics: Current Status and Future Directions.
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy.
PSMA Theranostics: Science and Practice.
PSMA Uptake in Mediastinal Sarcoidosis.
PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy.
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.
PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy.
PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.
PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach.
PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study.
PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy.
PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state.
PSMA-targeted contrast agents for intraoperative imaging of prostate cancer.
PSMA-targeted dendrimers: a patent evaluation (WO2012078534).
PSMA-targeted melanin-like nanoparticles as a multifunctional nanoplatform for prostate cancer theranostics.
PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617.
PSMA-Targeted Radiotherapy Extends Survival.
PSMA-targeted SPECT agents: Mode of binding effect on in vitro performance.
PSMA-Targeted Stably Linked "Dendrimer-Glutamate Urea-Methotrexate" as a Prostate Cancer Therapeutic.
Psma/Psa ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
Pulmonary Opacities and Bronchiectasis Avid on 68Ga-PSMA PET.
Pulmonary Vein Varix Mimicking Prostate Cancer Metastasis on 68Ga-Prostate Specific Membrane Antigen-11 PET/CT.
Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography.
Quality control and GMP synthesis of 68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer.
Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR.
Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients.
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.
Quantum dots for in vivo molecular and cellular imaging.
Radiation dosimetry and biodistribution of 18F-PSMA-11 for PET imaging of prostate cancer.
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
Radiation Dosimetry for (177)Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.
Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
Radiochemistry and Preclinical PET Imaging of
Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer.
Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro.
Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.
Radioimmunotherapy of Metastatic Prostate Cancer with ¹??Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter.
Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA.
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis.
Radiolabelled PSMA PET/CT in breast cancer. A systematic review.
Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG.
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
Radiopharmaceutical Therapy.
Radiotheranostics Using a Novel 225Ac-Labeled Radioligand with Improved Pharmacokinetics Targeting Prostate-Specific Membrane Antigen.
Rapid modulation of PSMA expression by Androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
Rare Sites of Metastases in Prostate Cancer Detected on Ga-68 PSMA PET/CT Scan-A Case Series.
Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery.
Rationally Designed Sulfamides As Glutamate Carboxypeptidase II (GCPII) Inhibitors.
Re: 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028.
Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656-61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists.
Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Lancet 2020;395:1208-16: PSMA Positron Emission Tomography: One Tracer Fixes Them All!
Re: Prostate cancer targeting motifs: expression of ?? ?3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts.
Re: Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Re: Prostate-specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-resistant Prostate Cancer.
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study.
Re: Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods.
Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.
Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.
Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells.
Recombinant glutamate carboxypeptidase II (prostate specific membrane antigen--PSMA)--cellular localization and bioactivity analyses.
Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer.
Rectal Carcinoma on 68Ga-PSMA PET/CT.
Recurrent Medullary Thyroid Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT: Exploring New Theranostic Avenues.
Reduction of (68)Ga-PSMA renal uptake with mannitol infusion: preliminary results.
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer.
Renal Pelvis Metastasis From Prostatic Adenocarcinoma Missed by PSMA PET: A Case Report.
Repeatability of 68Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
Repeatability of tumor blood flow quantification with 82Rubidium PET/CT in prostate cancer - a test-retest study.
Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen.
Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028: Despite its Slightly Limited Specificity, Prostate-specific Membrane Antigen Imaging is Still a Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy.
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy.
Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy.
Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.
Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.
Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread.
Rib Fractures Mimicking Bone Metastases in 18F-PSMA-1007 PET/CT for Prostate Cancer.
RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review.
Role of Early Dynamic Positron Emission Tomography/Computed Tomography with 68Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with Adenocarcinoma Prostate: Initial Results.
Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer.
Role of novel imaging in the management of prostate cancer.
Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer.
Role of salvage lymph node dissection in prostate cancer.
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status.
Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.
Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
Schwannoma Showing Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT.
Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer.
Selective gene therapy for prostate cancer cells using liposomes conjugated with IgM type monoclonal antibody against prostate-specific membrane antigen.
Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer.
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake.
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.
Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device.
Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen.
Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
Simple new method for labelling of PSMA-11 with 68Ga in NaHCO3.
Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a
Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer.
Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.
Simultaneous detection of circulating prostate specific antigen (PSA)-expressing and prostate specific membrane antigen (PSM)-expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.
Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer.
Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells.
Size Matters: Arginine-Derived Peptides Targeting the PSMA Receptor Can Efficiently Complex but Not Transfect siRNA.
Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.
Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (64Cu-PSMA PET/CT) in a patient with prostate cancer.
Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET.
Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68 Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant?
Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
Spectroscopy-Assisted Label-free Molecular Analysis of Live Cell Surface with Vertically Aligned Plasmonic Nanopillars.
Spinal Tuberculosis Mimicking as Prostate Cancer Metastases in Ga-68 Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography.
Spotlight on PSMA as a new theranostic biomarker for bladder cancer.
Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.
Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer.
State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer.
Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II.
Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III.
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.
Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from ?-amino acid with (S)- or (R)-configuration at P1' region.
Structure-activity relationships of 2',5'-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists.
Structure-activity relationships of succinimidyl-Cys-C(O)-Glu derivatives with different near-infrared fluorophores as optical imaging probes for prostate-specific membrane antigen.
Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
Sub-nanomolar detection of prostate-specific membrane antigen in synthetic urine by synergistic, dual-ligand phage.
Suramin potently inhibits the enzymatic activity of PSM.
Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer.
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer.
Synthesis and Binding of a Novel PSMA-specific Conjugate.
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA.
Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.
Synthesis and Biological Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for Positron Emission Tomography of Prostate Cancer.
Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them.
Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates.
Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.
Synthesis and Evaluation of 68Ga- and 177Lu-Labeled (R)- vs (S)-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives.
Synthesis and evaluation of a novel near-infrared fluorescent probe based on succinimidyl-Cys-C(O)-Glu that targets prostate-specific membrane antigen for optical imaging.
Synthesis and evaluation of a novel urea-based
Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen.
Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen.
Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of PSMA and Hypoxia for Prostate Cancer.
Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer.
Synthesis and evaluation of tumor-homing peptides for targeting prostate cancer.
Synthesis and evaluation of [(64)Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer.
Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity.
Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer.
Synthesis and in vitro preliminary evaluation of prostate-specific membrane antigen targeted upconversion nanoparticles as a first step towards radio/fluorescence-guided surgery of prostate cancer.
Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
Synthesis and positron emission tomography evaluation of (18)F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer.
Synthesis and preclinical evaluation of 68Ga-PSMA-BCH for prostate cancer imaging.
Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007.
Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.
Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.
Synthesis and SAR of ??mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates.
Synthesis of KUE-siRNA Conjugates for Prostate Cancer Cell-Targeted Gene Silencing.
Synthesis of novel multivalent fluorescent inhibitors with high affinity to prostate cancer and their biological evaluation.
Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion.
Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep.
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
Targeted ?-therapy in non-prostate malignancies.
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen).
Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells.
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors.
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-specific Membrane Antigen.
Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer.
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy.
Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway.
Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer.
Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance.
Targeted radionuclide therapy: an emerging field in solid tumours.
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Targeted therapies for prostate cancer against the prostate specific membrane antigen.
Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody.
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).
Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.
Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.
Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface?
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.
Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Targeting thapsigargin towards tumors.
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
Targeting the prostate-specific membrane antigen for prostate cancer therapy.
Targeting the spectrum of immune checkpoints in prostate cancer.
Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer.
Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/Millennium.
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
The (68)Ga/(177)Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
The application of the RT-PCR method for the staging of the prostate cancer progression.
The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.
The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
The emergence of radioimmunoscintigraphy for prostate cancer.
The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer.
The emerging value of 64Cu for molecular imaging and therapy.
The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.
The expression of prostate-specific membrane antigen in peripheral blood leukocytes.
The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.
The frequency of thyroid incidental findings and risk of malignancy detected by 68Ga-labeled prostate-specific membrane antigen PET/CT in prostate cancer.
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research.
The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study.
The impact of [
The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy.
The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer.
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.
The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
The Proinflammatory Cytokine, IL-6, and its Interference with bFGF Signaling and PSMA in Prostate Cancer Cells.
The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.
The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research.
The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery.
The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients.
The Role of Magnetic Resonance Imaging in (Future) Cancer Staging: Note the Nodes.
The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.
The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature.
The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer.
The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far.
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
The use of 68Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities.
The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations.
The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma.
The utility of radiolabeled PSMA ligands for tumor imaging.
The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Theranostics in oncology: What radiologists want to know.
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine.
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu.
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.
Thyroid Incidentaloma on 18F-fluorocholine PET/CT and 68Ga-PSMA PET/CT Revealing a Medullary Thyroid Carcinoma.
Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs.
Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer().
Tobacco mosaic virus for the targeted delivery of drugs to cells expressing prostate-specific membrane antigen.
Toward 18 F-Labeled Theranostics: A Single Agent that Can Be Labeled with 18 F, 64 Cu, or 177 Lu.
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
Translational Molecular Imaging of Prostate Cancer.
Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer.
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002).
Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents.
Tumor detection of 18F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method.
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?
Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer.
Ultrahigh affinity Raman probe for targeted live cell imaging of prostate cancer.
Ultrasensitive and Reversible Nanoplatform of Urinary Exosomes for Prostate Cancer Diagnosis.
Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood.
Ultrasmall Renally Clearable Silica Nanoparticles Target Prostate Cancer.
Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer.
Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy.
Upcoming Role of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Detecting Occult Metastases in Prostate Cancer.
Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.
Update on fused capromab pendetide imaging of prostate cancer.
Updates of prostate cancer staging: Prostate-specific membrane antigen.
Updates on the diagnosis and treatment of prostate cancer.
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).
Uptake of (18)F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies.
Uptake of an Acrochordon Incidentally Detected on 68Ga Prostate-Specific Membrane Antigen PET/CT.
Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head.
Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.
Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients.
Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer.
Utility of (68) Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.
Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
Utility of Ga68 prostate-specific membrane antigen positron-emission tomography for pre-operative staging of high-risk prostate cancer in a prospective cohort.
Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging.
Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Validation of a [Al
Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT.
Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer.
Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern.
Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
Virus electrodes for universal biodetection.
Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Visualizing Human Prostate Cancer Cells in Mouse Skeleton Using Bioconjugated Near-infrared Fluorescent Quantum Dots.
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer.
We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer.
Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen-a Possible Novel Therapeutic Target.
Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients.
What to Trust, PSA or [68Ga]Ga-PSMA-11: Learn from Experience.
What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer.
When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities.
Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer.
[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery.
[(18)F]-DCFPyL Positron Emission Tomography/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience.
[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
[18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice.
[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma.
[68Ga]Ga-iPSMA-Lys3-Bombesin: Biokinetics, dosimetry and first patient PET/CT imaging.
[68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.
[68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.
[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer.
[68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.
[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center.
[Advances in prostate-specific membrane antigen targeted therapies for prostate cancer]
[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
[Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients].
[Detection of PSA mRNA from the peripheral blood and pelvic lymph nodes in patients with prostatic cancer by means of reverse transcription-polymerase chain reaction (RT-PCR)]
[Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
[Ga-68-PSMA PET/CT for prostate cancer].
[Hybrid imaging in prostate cancer : Status quo and future applications].
[Initial experiences with 99mTc-PSMA-SPECT/CT in patients with prostate cancer].
[Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
[Modern radiation therapy planning and image-guided radiotherapy using the example of prostate cancer].
[Molecular multimodal hybrid imaging in prostate and bladder cancer].
[PET-CT and PET-MRI of the prostate : From (18)F-FDG to (68)Ga-PSMA].
[Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer].
[Positron-emission tomography in urooncology].
[Prostate-specific membrane antigen and its role in diagnosis of prostate cancer]
[Prostate-specific membrane antigen. A new sensitive molecular indicator in metastasizing prostatic cancer]
[PSMA-based theranostics for prostate cancer : From imaging to treatment].
[PSMA-radioguided surgery in localised recurrent prostate cancer].
[PSMA-targeted radioligand therapy in prostate cancer].
[Radionuclide therapy and diagnostics in urology].
[Recent progress of positron radionuclide labeled small molecule inhibitors of prostate specific membrane antigen for PET/CT imaging of prostate cancer].
[Related biomarkers in the diagnosis of prostate cancer].
[Salvage lymph node dissection for nodal recurrent prostate cancer].
[Significance of current bio- and molecular-markers in urological cancers]
[Significance of prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase]
[Significance of PSMA imaging in prostate cancer].
[The role of PSMA PET-CT in patients with metastatic prostate cancer].
[THE ROLE OF PSMA PET/CT IN IMAGING PROSTATE CANCER].
[Transcriptional activities of tumor-specific survivin promoter and PSMA promoter and enhancer in human prostate cancer: evaluation and comparison].
[Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer]
¹?F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Pulmonary Disease, Chronic Obstructive
Genetic analysis of 56 polymorphisms in 17 genes involved in methionine metabolism in patients with abdominal aortic aneurysm.
Ranula
Recalcitrant plunging ranulas: a new approach to salivary tissue localization using prostate-specific membrane antigen positron emission tomography.
Sarcoidosis
Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis.
Prostate-Specific Membrane Antigen PET/CT: Uptake in Lymph Nodes With Active Sarcoidosis.
Sarcoma
Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate Cancer.
Seizures
Kindling increases brain levels of NAAG and seizures reduce activity of a NAAG-hydrolyzing enzyme, NAALADase.
NAALADase (GCP II) inhibition prevents cocaine-kindled seizures.
Seizures decrease regional enzymatic hydrolysis of N-acetyl-aspartylglutamate in rat brain.
Sepsis
Core temperature correlates with expression of selected stress and immunomodulatory genes in febrile patients with sepsis and noninfectious SIRS.
Solitary Kidney
177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney.
Spinal Cord Injuries
Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats.
Spinal Dysraphism
Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk.
Splenosis
Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT.
Sprue, Tropical
Jejunal brush-border folate hydrolase. A novel enzyme.
Stroke
Biochemical characterization of human glutamate carboxypeptidase III.
Early-onset ischaemic stroke: analysis of 58 polymorphisms in 17 genes involved in methionine metabolism.
Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration.
Glutamate carboxypeptidase II (GCPII) genetic variants as determinants of hyperhomocysteinemia: implications in stroke susceptibility.
Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.
Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition.
Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury.
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Suppression of Glutamate Carboxypeptidase II Ameliorates Neuronal Apoptosis from Ischemic Brain Injury.
Testicular Neoplasms
PET imaging in urology: a rapidly growing successful collaboration.
Tetanus
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.
DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer.
Thymoma
Incidental Detection of Type B2 Thymoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT Imaging.
Thyroid Carcinoma, Anaplastic
Theranostics in Thyroid Cancer.
Thyroid Neoplasms
Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study.
Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing?
PSMA expression in differentiated thyroid cancer: association with radioiodine, 18FDG uptake, and patient outcome.
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome.
The frequency of thyroid incidental findings and risk of malignancy detected by 68Ga-labeled prostate-specific membrane antigen PET/CT in prostate cancer.
The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.
The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid Cancer.
Theranostics in Thyroid Cancer.
Triple Negative Breast Neoplasms
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
Tuberculosis, Spinal
Spinal Tuberculosis Mimicking as Prostate Cancer Metastases in Ga-68 Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography.
Urinary Bladder Neoplasms
Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature.
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Vascular Diseases
Influence of a glutamate carboxypeptidase II (GCPII) polymorphism (1561C-->T) on plasma homocysteine, folate and vitamin B(12) levels and its relationship to cardiovascular disease risk.
Whooping Cough
N-acetylaspartylglutamate and beta-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures.
Xerostomia
Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents.